Skip to content
ARON 3D_Transparent
  • Home
  • About Us
  • Contributors
  • Publications
    • Aron 1 – Renal Cell Carcinoma
    • Aron 2 – Urothelial carcinoma
    • Aron 3 – Prostate Cancer
    • Aron – supplementaries
  • Contact Us​
Menu
  • Home
  • About Us
  • Contributors
  • Publications
    • Aron 1 – Renal Cell Carcinoma
    • Aron 2 – Urothelial carcinoma
    • Aron 3 – Prostate Cancer
    • Aron – supplementaries
  • Contact Us​

Category: Publications

wealth of knowledge in the field of healthcare and medicine. Discover a curated selection of articles, research papers, and resources authored by esteemed professionals and leading experts in the medical community. From groundbreaking discoveries to practical insights and clinical guidelines, delve into the latest advancements, case studies, and discussions shaping the future of healthcare. Whether you’re a healthcare professional, student, or simply passionate about staying informed, explore our collection to expand your understanding and stay up-to-date with the latest trends and developments in the medical world.

Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study

Progetto senza titolo 2

Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study. 

8NFEVBrIQXOyNoE ypuJ Q

Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project 

I Q98Jc2TzefKFMEqz 1lw 1

Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project 

s4a1nnQeTsCmTjf dmcS8w

Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study

liqY6DfIRZ2ExhcXktzYsg

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study

H7MNXe MQ0GfFaBaXYUL2w

Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.

I Q98Jc2TzefKFMEqz 1lw

Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1)

9YIYKy5dR5CW5VFojEs66Q

Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study).

Y52i33xKRpGyTtsLtNDOuQ

Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations

ps65pqhOR 2z3PAYLdycAA
Next →

Do you want to join us ?

Join us today
ARON 3D_Transparent
Youtube Linkedin

Coordinated and designed by Atteggiamento Digitale .

Legal and Privacy.